# Repros Therapeutics Inc. clinical trials: 58 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 58 trials with Repros Therapeutics Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Repros Therapeutics Inc.: 58 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/repros-therapeutics-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 58
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 58, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 23, 2016 | NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed... | Repros Therapeutics Inc. | Phase 2 | Terminated | Uterine Fibroids | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02811159) |
| January 11, 2016 | NCT02651688 | A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters... | Repros Therapeutics Inc. | Phase 2 | Completed | Acquired Hypogonadotropic Hypogonadism, Obesity | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02651688) |
| December 23, 2014 | NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | Repros Therapeutics Inc. | Phase 2 | Completed | Uterine Fibroids | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02323646) |
| November 26, 2014 | NCT02301897 | A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone... | Repros Therapeutics Inc. | Phase 2 | Completed | Uterine Fibroids | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02301897) |
| October 24, 2014 | NCT02274181 | An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male... | Repros Therapeutics Inc. | Phase 1 | Completed | Secondary Hypogonadism | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02274181) |
| June 23, 2014 | NCT02169804 | An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal | Repros Therapeutics Inc. | Phase 1 | Completed | Pharmacokinetics | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02169804) |
| May 23, 2014 | NCT02146391 | Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal | Repros Therapeutics Inc. | Phase 1 | Completed | Normal Volunteers | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02146391) |
| May 19, 2014 | NCT02141061 | Comparison of Two Formulations of Proellex for Oral Administration | Repros Therapeutics Inc. | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02141061) |
| April 21, 2014 | NCT02117830 | A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects | Repros Therapeutics Inc. | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02117830) |
| November 25, 2013 | NCT01993225 | A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare... | Repros Therapeutics Inc. | Phase 3 | Completed | Secondary Hypogonadism | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01993225) |
| November 25, 2013 | NCT01993212 | A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare... | Repros Therapeutics Inc. | Phase 3 | Completed | Secondary Hypogonadism | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01993212) |
| November 25, 2013 | NCT01991327 | Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males | Repros Therapeutics Inc. | Phase 1 | Completed | Drug-drug Interaction | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01991327) |
| November 14, 2013 | NCT01984398 | Comparison of Two Formulations of Androxal | Repros Therapeutics Inc. | Phase 1 | Completed | Bioequivalence | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01984398) |
| October 14, 2013 | NCT01962805 | Comparison of Two Formulations of Proellex for Vaginal Administration | Repros Therapeutics Inc. | Phase 1 | Completed | Comparison of 2 Different Formulations of 12 mg Proellex Vaginal Capsules | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01962805) |
| October 14, 2013 | NCT01961908 | Open-Label Extension Study to ZPE-202 | Repros Therapeutics Inc. | Phase 2 | Withdrawn | Endometriosis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01961908) |
| October 10, 2013 | NCT01959685 | A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal | Repros Therapeutics Inc. | Phase 1 | Completed | Pharmacokinetics, Tolerability | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01959685) |
| August 16, 2013 | NCT01923870 | Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function | Repros Therapeutics Inc. | Phase 1 | Completed | Secondary Hypogonadism | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01923870) |
| August 16, 2013 | NCT01923857 | Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function | Repros Therapeutics Inc. | Phase 1 | Completed | Secondary Hypogonadism | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01923857) |
| December 3, 2012 | NCT01739621 | Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women... | Repros Therapeutics Inc. | Phase 2 | Completed | Uterine Fibroids | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01739621) |
| December 3, 2012 | NCT01739595 | Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism | Repros Therapeutics Inc. | Phase 3 | Completed | Secondary Hypogonadism | 181 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01739595) |
| December 3, 2012 | NCT01739582 | An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | Repros Therapeutics Inc. | Phase 3 | Completed | Secondary Hypogonadism | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01739582) |
| November 19, 2012 | NCT01728454 | Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis | Repros Therapeutics Inc. | Phase 2 | Completed | Endometriosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01728454) |
| June 29, 2012 | NCT01631903 | Extension of Study ZPV-200 | Repros Therapeutics Inc. | Phase 2 | Completed | Uterine Fibroids | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01631903) |
| June 14, 2012 | NCT01619683 | Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism | Repros Therapeutics Inc. | Phase 3 | Completed | Effect of Treatment on Bone Mineral Density | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01619683) |
| February 16, 2012 | NCT01534208 | Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism | Repros Therapeutics Inc. | Phase 3 | Completed | Secondary Hypogonadism | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01534208) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 19 |
| Phase 1/2 | 3 |
| Phase 2 | 20 |
| Phase 3 | 16 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 43 |
| Terminated | 13 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leiomyoma | 18 |
| Hypogonadism | 16 |
| Endometriosis | 4 |
| Pelvic Pain | 2 |
| Anemia | 2 |
| Amenorrhea | 2 |
| Fibroma | 1 |
| Liver Diseases | 1 |
| Obesity | 1 |
| Renal Insufficiency | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Myofibroma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Belgian restaurants in the United States](https://specstream.ai/data/businesses/belgian-restaurants/united-states)
- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Damage restoration companies in the United States](https://specstream.ai/data/businesses/damage-restoration-companies/united-states)
- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
- [Aircraft parts suppliers in the United States](https://specstream.ai/data/businesses/aircraft-parts-suppliers/united-states)
